PWS
VRTX icon

Peloton Wealth Strategists’s Vertex Pharmaceuticals VRTX Stock Holding History

Peloton Wealth Strategists’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.61M Buy
9,280
+140
+2% +$62K 1.7% 21
2026
Q1 		$4.08M Buy
9,140
+100
+1% +$46.6K 1.65% 20
2025
Q4 		$4.1M Buy
9,040
+1,165
+15% +$502K 1.59% 22
2025
Q3 		$3.08M Sell
7,875
-275
-3% -$115K 1.21% 29
2025
Q2 		$3.63M Buy
8,150
+196
+2% +$90.3K 1.46% 24
2025
Q1 		$3.86M Buy
7,954
+1,920
+32% +$895K 1.61% 21
2024
Q4 		$2.43M Buy
6,034
+3,859
+177% +$1.79M 0.98% 37
2024
Q3 		$1.01M Buy
2,175
+1,600
+278% +$769K 0.4% 67
2024
Q2 		$270K Buy
+575
New +$250K 0.11% 89

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Peloton Wealth Strategists's VRTX Position: Q2 2026 in Review

Peloton Wealth Strategists increased its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q2 2026, buying an estimated $62K and bringing the position to 9,280 shares worth $4.61M. The position accounts for 1.7% of the portfolio, ranked #21.

Peloton Wealth Strategists first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Peloton Wealth Strategists held 9,280 shares of Vertex Pharmaceuticals worth $4.61M as of Q2 2026.
  • Peloton Wealth Strategists bought 140 Vertex Pharmaceuticals shares in Q2 2026, an estimated $62K.
  • Vertex Pharmaceuticals made up 1.7% of Peloton Wealth Strategists's portfolio in Q2 2026, its #21 holding.
  • Peloton Wealth Strategists first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Peloton Wealth Strategists's 13F filing for Q2 2026, filed 10 Aug 2026.